For example, Dales et al have demonstrated an increased expression of VEGF-R1 in diseases such as breast cancer, a disease in which VEGF-R1 seems to be a negative prognostic marker with a high risk of metastases and relapses [135] and the use of antibodies against VEGF-R1 determines a powerful inhibition of neoplastic cell growth [136]. The gene discussed is FLT1; the disease is breast carcinoma.